Charlotte H. Ahern

2.6k total citations · 1 hit paper
42 papers, 2.0k citations indexed

About

Charlotte H. Ahern is a scholar working on Oncology, Neurology and Molecular Biology. According to data from OpenAlex, Charlotte H. Ahern has authored 42 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 19 papers in Neurology and 14 papers in Molecular Biology. Recurrent topics in Charlotte H. Ahern's work include Neuroblastoma Research and Treatments (18 papers), Pancreatic and Hepatic Oncology Research (11 papers) and Virus-based gene therapy research (4 papers). Charlotte H. Ahern is often cited by papers focused on Neuroblastoma Research and Treatments (18 papers), Pancreatic and Hepatic Oncology Research (11 papers) and Virus-based gene therapy research (4 papers). Charlotte H. Ahern collaborates with scholars based in United States, Canada and Switzerland. Charlotte H. Ahern's co-authors include Susan M. Blaney, Brenda J. Weigel, Ashish M. Ingle, Peter C. Adamson, Stephan D. Voss, Joel M. Reid, Yaël P. Mossé, John M. Maris, Julie Laliberté and Megan S. Lim and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Charlotte H. Ahern

42 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

2013 477 citations Yaël P. Mossé, Megan S. Lim et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Charlotte H. Ahern

Since Specialization

Citations

This map shows the geographic impact of Charlotte H. Ahern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charlotte H. Ahern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charlotte H. Ahern more than expected).

Fields of papers citing papers by Charlotte H. Ahern

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charlotte H. Ahern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charlotte H. Ahern. The network helps show where Charlotte H. Ahern may publish in the future.

Co-authorship network of co-authors of Charlotte H. Ahern

This figure shows the co-authorship network connecting the top 25 collaborators of Charlotte H. Ahern. A scholar is included among the top collaborators of Charlotte H. Ahern based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charlotte H. Ahern. Charlotte H. Ahern is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report 2014 ·Clinical Cancer Research ·Maryam Fouladi, John P. Perentesis, Lars M. Wagner, Alexander A. Vinks, Joel M. Reid, Charlotte H. Ahern, George Thomas, Carol A. Mercer, Darcy A. Krueger, Peter J. Houghton, L. Austin Doyle, Helen Chen, Brenda J. Weigel, Susan M. Blaney	16
2	Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk 2014 ·British Journal of Cancer ·Charlotte H. Ahern, Ya‐Chen Tina Shih, Wenli Dong, Giovanni Parmigiani, Yu Shen	38
3	A phase 1 study of the c-Met inhibitor tivantinib (ARQ 197, IND#112603) in children with relapsed or refractory solid tumors: A Children’s Oncology Group study. 2014 ·Journal of Clinical Oncology ·James I. Geller, John P. Perentesis, Charlotte H. Ahern, Rachel A. Kudgus, Elizabeth Fox, Susan M. Blaney, Brenda J. Weigel	1
4	A phase I study of ruxolitinib in children with relapsed/refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group Phase I Consortium study (ADVL1011). 2014 ·Journal of Clinical Oncology ·Sarah K. Tasian, Mignon L. Loh, Karen R. Rabin, Patrick A. Brown, Charlotte H. Ahern, Brenda J. Weigel, Susan M. Blaney	1
5	Phase I trial of Seneca Valley Virus (NTX‐010) in children with relapsed/refractory solid tumors: A report of the Children's Oncology Group 2014 ·Pediatric Blood & Cancer ·Michael J. Burke, Charlotte H. Ahern, Brenda J. Weigel, John T. Poirier, Charles M. Rudin, Ying‐Bei Chen, Timothy P. Cripe, M. Brooke Bernhardt, Susan M. Blaney	65
6	Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children With Soft Tissue Sarcoma and Other Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report 2013 ·Journal of Clinical Oncology ·Julia Glade Bender, Alice Lee, Joel M. Reid, Sylvain Baruchel, Timothy P. L. Roberts, Stephan D. Voss, Bing Wu, Charlotte H. Ahern, Ashish M. Ingle, Pamela Jo Harris, Brenda J. Weigel, Susan M. Blaney	125
7	Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study breakdown → 2013 ·The Lancet Oncology ·Yaël P. Mossé, Megan S. Lim, Stephan D. Voss, Keith D. Wilner, Katherine Ruffner, Julie Laliberté, Delphine Rolland, Frank M. Balis, John M. Maris, Brenda J. Weigel, Ashish M. Ingle, Charlotte H. Ahern, Peter C. Adamson, Susan M. Blaney	477
8	A Phase I Trial of Imetelstat in Children with Refractory or Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Study (ADVL1112) 2013 ·Clinical Cancer Research ·Patrick A. Thompson, Rachid Drissi, Jodi A. Muscal, Eshini Panditharatna, Maryam Fouladi, Ashish M. Ingle, Charlotte H. Ahern, Joel M. Reid, Tong Lin, Brenda J. Weigel, Susan M. Blaney	61
9	Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A children's oncology group study 2013 ·Pediatric Blood & Cancer ·Rochelle Bagatell, Robin E. Norris, Ashish M. Ingle, Charlotte H. Ahern, Stephan D. Voss, Elizabeth Fox, (unknown), Brenda J. Weigel, Peter C. Adamson, Susan M. Blaney	83
10	A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report 2012 ·Clinical Cancer Research ·Julia Glade Bender, Susan M. Blaney, Scott C. Borinstein, Joel M. Reid, Sylvain Baruchel, Charlotte H. Ahern, Ashish M. Ingle, Darrell J. Yamashiro, Alice P. Chen, Brenda J. Weigel, Peter C. Adamson, Julie R. Park	16
11	A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group phase I consortium study (ADVL0916) 2012 ·Pediatric Blood & Cancer ·Jodi A. Muscal, Patrick A. Thompson, Terzah M. Horton, Ashish M. Ingle, Charlotte H. Ahern, Renee M. McGovern, Joel M. Reid, Matthew M. Ames, Igor Espinoza‐Delgado, Brenda J. Weigel, Susan M. Blaney	66
12	Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma: A Report From the Children's Oncology Group 2011 ·Journal of Clinical Oncology ·Suman Malempati, Brenda J. Weigel, Ashish M. Ingle, Charlotte H. Ahern, Julie M. Carroll, Charles T. Roberts, Joel M. Reid, Stephen C. Schmechel, Stephan D. Voss, (unknown), Helen X. Chen, Mark Krailo, Peter C. Adamson, Susan M. Blaney	147
13	Pancreatic resection without routine intraperitoneal drainage 2011 ·HPB ·William E. Fisher, Sally E. Hodges, Eric J. Silberfein, Avo Artinyan, Charlotte H. Ahern, Eunji Jo, F. Charles Brunicardi	83
14	Risk-Specific Optimal Cancer Screening Schedules: An Application to Breast Cancer Early Detection 2011 ·Statistics in Biosciences ·Charlotte H. Ahern, (unknown), Yu Shen	5
15	Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children’s Oncology Group study 2011 ·Cancer Chemotherapy and Pharmacology ·Steven G. DuBois, Suzanne Shusterman, Joel M. Reid, Ashish M. Ingle, Charlotte H. Ahern, Sylvain Baruchel, Julia Glade Bender, Percy Ivy, Peter C. Adamson, Susan M. Blaney	32
16	A pediatric phase I trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A Children’s Oncology Group Phase I Consortium Study. 2011 ·Journal of Clinical Oncology ·Trent R. Hummel, Lars M. Wagner, Charlotte H. Ahern, Renee M. McGovern, Matthew M. Ames, Richard J. Gilbertson, (unknown), (unknown), Brenda J. Weigel, Susan M. Blaney, (unknown)	4
17	Obesity Does Not Increase Complications Following Pancreatic Surgery 2011 ·Journal of Surgical Research ·Courtney J. Balentine, José M. Enríquez–Navascués, (unknown), Sally E. Hodges, Vivek Bansal, Eunji Jo, Charlotte H. Ahern, Shubhada Sansgiry, Nancy J. Petersen, Eric J. Silberfein, F. Charles Brunicardi, David H. Berger, William Fisher	26
18	Down-regulation of ZIP4 by RNA Interference Inhibits Pancreatic Cancer Growth and Increases the Survival of Nude Mice with Pancreatic Cancer Xenografts 2009 ·Clinical Cancer Research ·Min Li, Yu‐Qing Zhang, Uddalak Bharadwaj, Qihui Zhai, Charlotte H. Ahern, William E. Fisher, F. Charles Brunicardi, Craig D. Logsdon, Changyi Chen, Qizhi Yao	86
19	A phase I trial and pharmacokinetic study of IMC-A12 in pediatric patients with relapsed/refractory solid tumors: A Children's Oncology Group Phase I Consortium study 2009 ·Journal of Clinical Oncology ·Suman Malempati, Brenda J. Weigel, (unknown), Charlotte H. Ahern, Julie M. Carroll, (unknown), Floyd E. Fox, Stephan D. Voss, Peter C. Adamson, Susan M. Blaney	10
20	Cost-Effectiveness Analysis of Mammography and Clinical Breast Examination Strategies: A Comparison with Current Guidelines 2009 ·Cancer Epidemiology Biomarkers & Prevention ·Charlotte H. Ahern, Yu Shen	40

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact